IC
BCLI

Ikarian Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Ikarian Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,016
Closed -$13.7K – 171
2024
Q4 		$13.7K Buy
+6,016
New +$11.1K ﹤0.01% 165
2024
Q3 		– Sell
-6,016
Closed -$30.5K – 157
2024
Q2 		$30.5K Hold
6,016
– – 0.01% 112
2024
Q1 		$51K Hold
6,016
– – 0.01% 131
2023
Q4 		$24.6K Hold
6,016
– – ﹤0.01% 131
2023
Q3 		$18.1K Sell
6,016
-6,646
-52% -$151K ﹤0.01% 136
2023
Q2 		$391K Hold
12,662
– – 0.06% 102
2023
Q1 		$627K Hold
12,662
– – 0.14% 90
2022
Q4 		$311K Hold
12,662
– – 0.08% 68
2022
Q3 		$839K Sell
12,662
-4,233
-25% -$212K 0.17% 73
2022
Q2 		$698K Sell
16,895
-3,382
-17% -$152K 0.13% 92
2022
Q1 		$1.02M Buy
20,277
+974
+5% +$47.8K 0.13% 100
2021
Q4 		$1.16M Hold
19,303
– – 0.17% 95
2021
Q3 		$955K Sell
19,303
-244
-1% -$12.8K 0.07% 158
2021
Q2 		$1.11M Hold
19,547
– – 0.09% 155
2021
Q1 		$1.12M Buy
+19,547
New +$1.48M 0.04% 235

Other funds holding BCLI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ikarian Capital's BCLI Position: Q1 2025 in Review

Ikarian Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 6,016 shares — an estimated $13.7K sold.

Ikarian Capital first reported a position in BCLI in Q1 2021 and held it in 15 quarters. The position peaked at $1.16M in Q4 2021. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

  • Ikarian Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 6,016 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $13.7K.
  • Ikarian Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 15 quarters.
  • Ikarian Capital's BRAINSTORM CELL THERAPUTC position peaked at $1.16M in Q4 2021.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.